奈达铂联合5-氟尿嘧啶新辅助化疗食管癌手术患者的疗效观察  

Clinical study of nedaplatin combined with 5-FU in neo-adjuvant chemotherapy for esophageal cancer patients

作　　者：田敬荣 苗毅[2] 何新梅[1] 李晓敏[1] 赵玉芹[1] 王菊美[1] 

机构地区：[1]河北省邯郸市中心医院肿瘤内科,河北邯郸056001 [2]河北省邯郸市中心医院心脏血管外科,河北邯郸056001

出　　处：《河北医科大学学报》2016年第8期897-899,共3页Journal of Hebei Medical University

摘　　要：目的观察奈达铂联合5-氟尿嘧啶（5-fluorouracil,5-FU）新辅助化疗对食管癌手术患者的疗效和安全性。方法选取72例食管癌患者随机分为治疗组和对照组各36例。治疗组术前采用奈达铂联合5-FU化疗2个周期,化疗结束后3~4周进行手术治疗;对照组直接进行手术切除。对比2组治疗根治性切除率、术后并发症发生率以及术后3年生存率。结果 2组均顺利完成手术,治疗组手术根治性切除率为88.9%,术后并发症发生率为41.7%,术后3年生存率为60.0%;对照组则分别为69.4%、36.1%、34.3%。2组根治性切除率及术后3年的生存率差异有统计学意义,术后并发症发病率差异无统计学意义。结论奈达铂联合5-FU新辅助化疗可显著提高食管癌根治性切除率,提高患者的生存率,不增加并发症的发生率,值得临床上推广使用。Objective To detect the clinical efficacy and safety of neo-adjuvant chemotherapy with nedaplatin and 5-fluorouracil（5-FU）for the patients with esophageal cancer.Methods A total of 72 patients with esophageal cancer randomly divided into treatment group（36cases）and control group（36cases）.Treatment group received neo-adjuvant chemotherapy with nedaplatin and 5-FU for 2cycles and underwent operation 3-4weeks after chemotherapy.The patients of control group were treated with operation alone.The radical resection rate,postoperative complication rate and three-year survival rate were compared between the two groups.ResultsThe patients of two groups were successfully completed the operation.The radical resection rate,postoperative complication rate,three-year survival rate of the treatment group were 88.9%,41.7%,60.0% and those of control group were 69.4%,36.1%,34.3%,respectively.The radical resection rate and three-years survival rate between the two groups were significantly different,but there was no significant difference in postoperative complication rate.ConclusionNedaplatin in neo-adjuvant chemotherapy for esophageal cancer could significantly increase radical resection rate and three-year survival rate and presented no negative influence on thepostoperative complication rate,which is worthy of clinical application.

关 键 词：食管肿瘤 氟尿嘧啶 放化疗 辅助 

分 类 号：R735.1[医药卫生—肿瘤]